Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 5:24:100-106.
doi: 10.1016/j.jmsacl.2022.04.005. eCollection 2022 Apr.

Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS

Amol O Bajaj  1 , Diane Ly  1 , Kamisha L Johnson-Davis  1   2
Affiliations

Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS

Amol O Bajaj et al. J Mass Spectrom Adv Clin Lab. .

Abstract

Introduction: Clobazam is a benzodiazepine drug, used to treat Lennox-Gastaut syndrome in patients aged 2 years and older.

Objective: To support patient care, our laboratory developed a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of clobazam (CLB) and its major active metabolite N-desmethylclobazam (N-CLB) in human plasma or serum samples.

Methods: The chromatographic separation was achieved with an Agilent Zorbax Eclipse Plus C-18 RRHD column with mobile phase consisting of 0.05% formic acid in 5 mM ammonium formate, pH 3.0 and 0.1% formic acid in acetonitrile at a flow rate of 600 µL/minute and an injection volume of 5 µL. The detection was performed on a triple quadrupole mass spectrometer in multiple reaction monitoring mode to monitor precursor-to-product ion transitions in positive electrospray ionization mode.

Results: The method was validated over a concentration range of 20-2000 ng/mL for CLB and 200-10,000 ng/mL for N-CLB. The lower limit of quantification was 20 ng/mL for CLB and 200 ng/mL for N-CLB with good accuracy and precision. The method performance was successfully evaluated by comparison with two different external laboratories. Retrospective data analysis was performed to evaluate the positivity rate and metabolic patterns for clobazam from our patient population, as a reference laboratory. Among the positive samples, both parent and metabolite were detected in 96.4% of the samples.

Conclusion: The method was developed to support therapeutic drug monitoring and the data generated from retrospective analysis could be useful for result interpretation in conjunction with clinical patient information.

Keywords: CLB, Clobazam; CLIA, Clinical Laboratory Improvement Amendment; CLRW, Clinical Laboratory Reagent Water; Clobazam; DAD, Diode Array Detector; ESI, Electrospray ionization; IRB, Institutional Review Board; LC-MS/MS; LC-MS/MS, liquid chromatography tandem mass spectrometry; LLOQ, lower limit of quantification; LOD, limit of detection; MRM, multiple reaction monitoring; N-CLB, N-desmethylclobazam; N-Desmethylclobazam; Plasma; Retrospective data analysis; TDM, Therapeutic drug monitoring; ULOQ, upper limit of quantification; UV, Ultraviolet.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Chromatography of clobazam and N-desmethylclobazam at the LLOQ (no color).
Fig. 2
Fig. 2
Method comparison for clobazam comparing ARUP Laboratories with Lab A and Lab B (no color).
Fig. 3
Fig. 3
Method comparison for N-desmethylclobazam comparing ARUP Laboratories and Lab B.
Fig. 4
Fig. 4
Ion Trace for Suppression Studies at 400/2000 ng/mL of CLB/N-CLB (no color).
Fig. 5
Fig. 5
The distribution of ratios of N-desmethylclobazam/clobazam in serum/plasma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McCall W.V. A psychiatric perspective on insomnia. J. Clin. Psychiatry. 2001;62(Suppl 10):27–32. - PubMed
    1. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011;10(9):685–697. - PMC - PubMed
    1. Onfi (clobazam). [cited 2022 February 25]; Available from: https://www.onfi.com/.
    1. Moosmann, B., L.A. King, and V. Auwärter, Designer benzodiazepines: A new challenge. World Psychiatry, 2015. 14(2): p. 248. - PMC - PubMed
    1. Garretty D.J., Wolff K., Hay A.W.M., Raistrick D. Benzodiazepine misuse by drug addicts. Ann. Clin. Biochem. 1997;34(1):68–73. - PubMed

LinkOut - more resources